The potential value of thrombin generation assay in the diagnosis of FV inhibitors

Désage, Stéphanie; Jousselme, Emilie; Quellec, Sandra Le; Lienhart, Anne; Nougier, Christophe; Dargaud, Yesim; Jourdy, Yohann

doi:10.1111/ijlh.13027

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGA has been proposed to identify the effect of the factor‐specific inhibitors on coagulation and possibly better identify patients at risk of bleeding. Furthermore, TGA could be an additional tool to select the most appropriate bypassing agent when required 15 …”

Section: Clinical and Diagnostic Applications In Bleeding Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Clinical use of thrombin generation assays

Binder

Depasse

Müeller

et al. 2021

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Determining patient's coagulation profile, i.e. detecting a bleeding tendency or the opposite, a thrombotic risk, is crucial for clinicians in many situations. Routine coagulation assays and even more specialized tests may not allow a relevant characterization of the hemostatic balance. In contrast, thrombin generation assay (TGA) is a global assay allowing the dynamic continuous and simultaneous recording of the combined effects of both thrombin generation and thrombin inactivation. TGA thus reflects the result of procoagulant and anticoagulant activities in blood and plasma. Because of this unique feature, TGA has been widely used in a wide array of settings from both research, clinical and pharmaceutical perspectives. This includes diagnosis, prognosis, prophylaxis, and treatment of inherited and acquired bleeding and thrombotic disorders. In addition, TGA has been shown to provide relevant information for the diagnosis of coagulopathies induced by infectious diseases, comprising also disturbance of the coagulation system in COVID‐19, or for the assessment of early recurrence in breast cancer. This review article aims to document most clinical applications of TGA.

show abstract

Section: Clinical and Diagnostic Applications In Bleeding Disordersmentioning

confidence: 99%

“…Furthermore, TGA could be an additional tool to select the most appropriate bypassing agent when required. 15 …”

Section: Clinical and Diagnostic Applications In Bleeding Disordersmentioning

confidence: 99%

Clinical use of thrombin generation assays

Binder

Depasse

Müeller

et al. 2021

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Activation of factor V by thrombin is achieved through a series of proteolytic cleavages. Activated factor V was inactivated by activated protein C in a surface dependent reaction that requires calcium ion and protein S. 9 Our patient presented with history and features which overlapped with the features of Haemophilia B and Von Willebrand Disease. These overlapping features posed a diagnostic dilemma.…”

Section: Discussionmentioning

confidence: 59%

Parahaemophilia: A Rare Case Report

Bhuiyan

Giti

Khan

et al. 2020

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Parahaemophilia or Owren’s diseaseis a rare haemorrhagic disorder occurs due to congenital and frequently familial deficiency of Factor V.It is characterized by epistaxis, bruising, mucosal bleeding, soft tissue bleeding and haemarthrosis. We report a case of 6 year old female patient with overlapping features with other haemorrhagic disorder. With the complaints of recurrent episodic per rectal bleeding, patient was evaluated at different hospitals in Chattagram and was diagnosed as a case of Haemophilia B and treated accordingly. As her condition was not improved expectedly, she was referred to Armed Forces Institute of Pathology (AFIP) for further evaluation. The lab tests showed prolongation of prothrombin time (PT) and activated partial thromboplastin time (APTT), with normal bleeding time (BT) and thrombin time (TT). Coagulation factors assay revealed a significant decrease of factor V, 1% of normal range. Other coagulation factors are normal. She was treated with FFP and recovered four weeks after treatment. J Bangladesh Coll Phys Surg 2020; 38(4): 205-208

show abstract

The potential value of thrombin generation assay in the diagnosis of FV inhibitors

Cited by 2 publications

References 6 publications

Clinical use of thrombin generation assays

Clinical use of thrombin generation assays

Parahaemophilia: A Rare Case Report

Contact Info

Product

Resources

About